Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

Spero Therapeutics reported a significantly narrowed Q2 2025 net loss of $1.7 million, driven by increased collaboration revenue from GSK and reduced R&D expenses. The company's lead asset, Tebipenem HBr, successfully met its primary endpoint in the Phase III PIVOT-PO trial for complicated urinary tract infections (cUTIs), demonstrating non-inferiority to IV imipenem-cilastatin and leading to early trial cessation. This positive outcome positions Tebipenem HBr as a potential first oral carbapenem for cUTIs, with GSK planning a U.S. regulatory filing by year-end 2025, potentially triggering up to $351 million in contingent milestones for Spero and extending its cash runway into 2028. Conversely, the SPR720 program for Nontuberculous mycobacterial pulmonary disease did not meet its primary endpoint in a Phase IIa study, with the company assessing its future.

Analysis

Spero Therapeutics has reported a pivotal quarter, fundamentally de-risking its lead asset, Tebipenem HBr, and significantly strengthening its financial position. The primary catalyst was the early cessation of the Phase III PIVOT-PO trial for efficacy, where Tebipenem HBr demonstrated non-inferiority to the IV standard of care for complicated urinary tract infections (cUTIs). This positive outcome, achieved under a Special Protocol Assessment with the FDA, positions the drug for a regulatory submission by partner GSK planned for year-end 2025. The early trial stop has generated material cost savings, directly contributing to an extended cash runway now projected into 2028 and a sharp reduction in quarterly net loss to $1.7 million from $17.9 million year-over-year. This financial stability is further supported by a strong partnership with GSK, which is responsible for regulatory and commercialization costs and from whom Spero stands to receive up to $351 million in contingent milestones plus royalties. However, the company's pipeline has narrowed, as its other clinical-stage asset, SPR720, failed to meet its primary endpoint in a Phase IIa study due to insufficient efficacy and potential safety concerns, effectively making Spero a single-asset story centered on the successful approval and commercialization of Tebipenem HBr.

Key Decisions for Investors

• The positive Phase III data for Tebipenem HBr represents a significant de-risking event, and investors should view the planned regulatory filing by GSK at year-end 2025 as the next major valuation catalyst, potentially unlocking a $25 million milestone payment.
• With a cash runway extended into 2028 and a substantially lower burn rate, the immediate risk of shareholder dilution is minimized, allowing the market to focus on the long-term value of the GSK partnership and future royalty stream.
• Investors must recognize that Spero's value is now heavily concentrated on a single asset following the failure of the SPR720 program; therefore, any potential delays in regulatory timelines or challenges in commercial execution by GSK represent the primary risks to the investment thesis.